BioSpace News Archive

Drug Development

Novartis Buys IFM Tre in Deal That Could Hit $1.6 Billion

Novartis will pay $310 million upfront for the Boston-based inflammation company IFM Tre. IFM TRE is very much an early-stage company, with one compound, IFM-2427, in an early Phase I clinical trial, and two preclinical assets.

April 1, 2019
·
3 min read
·
Mark Terry
Drug Development

FDA Green-Lights EMD Serono’s Mavenclad for Multiple Sclerosis in the U.S.

EMD Serono, a unit of Merck KGaA, Darmstadt, Germany, announced that the U.S. Food and Drug Administration (FDA) had approved Mavenclad (cladribine) for adults with relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive disease (SPMS).

April 1, 2019
·
2 min read
·
Mark Terry
Drug Development

Pfizer Spinout SpringWorks Nabs $125 Million to Advance Candidates Into Late-Stage Trials

The late-stage studies funded by the financing round could set the stage for two potential regulatory approvals if the data remains strong.

April 1, 2019
·
2 min read
·
Alex Keown
Deals

Starboard Value Backs Down From BMS/Celgene Fight After Proxy Advisory Firms Announce Support

Shares of Bristol-Myers Squibb are up slightly this morning after the proposed $74 billion acquisition of Celgene gained some significant support over the weekend. That support has caused at least one opposition group to withdraw from the fight.

April 1, 2019
·
3 min read
·
Alex Keown
Deals

PureTech Health Affiliate Karuna Therapeutics Completes Extended $80 Million Series B Financing

Funding to drive investigation of further potential indications for lead product candidate, KarXT First U.S. Patent awarded for KarXT

April 1, 2019
·
8 min read
Drug Development

NOXXON PRESENTS UPDATED RESULTS FROM PHASE 1/2 NOX-A12 / KEYTRUDA® COMBINATION TRIAL AT AACR 2019

NOXXON Pharma N.V. announced the latest update of clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the American Association for Cancer Research Annual Meeting.

April 1, 2019
·
3 min read
Drug Development

Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results

Study 3 Demonstrated Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP in Patients Considered Statin Intolerant

April 1, 2019
·
9 min read
Pharm Country

AACR Roundup: Cancer Vaccines, New Approaches to Immuno-Oncology and More

The American Association for Cancer Research (AACR) Annual Meeting is ongoing in Atlanta, with plenty of companies presenting interesting and cutting-edge science. Here’s a look at just a representative few.

April 1, 2019
·
3 min read
·
Mark Terry
Drug Development

Genetown, a Hotbed of Innovation and Drug Development

The lynchpin to biotech and pharmaceutical drug development in the United States is arguably the greater Boston area, which includes the white hot square mile of talent and intellectual collaboration found in Kendall Square.

April 1, 2019
·
4 min read
·
Alex Keown
Deals

Evotec AG Completes Conversion Into Evotec SE

Evotec SE announced that it has completed its conversion into a company under European law with its registration in the commercial register of the District Court of Hamburg.

April 1, 2019
·
3 min read